

BIOCON GROUP

FACT SHEET

September - 2021

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q2'FY 22	Q2'FY 21	Variance %
INCOME			
Generics	530	604	-12%
Biosimilars	743	676	10%
Novel Biologics	12	-	-
Research services	610	520	17%
Inter-segment	(54)	(50)	9%
Revenue from operations #	1,840	1,750	5%
Other income	105	16	577%
TOTAL REVENUE	1,945	1,765	10%
EXPENDITURE			
Material & Power costs	641	606	6%
Staff costs	437	383	14%
Research & Development expenses*	146	148	-1%
Other expenses	170	222	-23%
Manufacturing, staff & other expenses	1,395	1,358	3%
EBITDA	551	407	35%
Interest & Finance charges	23	7	246%
Depreciation & Amortisation	202	178	13%
Share of loss / (profit) in JV / Associate, net	51	5	100%
PBT BEFORE EXCEPTIONAL ITEM	276	218	27%
Exceptional item	(70)	-	-
PBT	206	218	-5%
Taxes	59	22	163%
Taxes on exceptional item	(12)	-	0%
NET PROFIT BEFORE MINORITY INTEREST	160	195	-18%
Minority interest	29	26	13%
Minority interest on exceptional item	(8)	-	-
NET PROFIT FOR THE PERIOD	138	169	-18%
EPS Rs.	1.2	1.4	
NET PROFIT BEFORE EXCEPTIONAL ITEM	188	169	11%
Exceptional item, net of taxes	(50)	-	0%
NET PROFIT FOR THE PERIOD	138	169	-18%
<i># Licensing Income</i>	13	10	
<i>* Gross Research & Development expenses</i>	165	165	

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q2' FY 22	Q1' FY 22	Variance %
INCOME			
Generics	530	486	9%
Biosimilars	743	758	-2%
Novel Biologics	12	11	-
Research services	610	595	3%
Inter-segment	(54)	(89)	-39%
Revenue from operations #	1,840	1,761	5%
Other income	105	47	122%
TOTAL REVENUE	1,945	1,808	8%
EXPENDITURE			
Material & Power costs	641	686	-7%
Staff costs	437	395	11%
Research & Development expenses*	146	120	22%
Other expenses	170	171	0%
Manufacturing, staff & other expenses	1,395	1,371	2%
EBITDA	551	437	26%
Interest & Finance charges	23	20	13%
Depreciation & Amortisation	202	195	3%
Share of loss / (profit) in JV / Associate, net	51	56	100%
PBT BEFORE EXCEPTIONAL ITEM	276	166	67%
Exceptional item	(70)	-	-
PBT	206	166	24%
Taxes	59	57	2%
Taxes on exceptional item	(12)	-	0%
NET PROFIT BEFORE MINORITY INTEREST	160	108	47%
Minority interest	29	24	23%
Minority interest on exceptional item	(8)	-	-
NET PROFIT FOR THE PERIOD	138	84	64%
EPS Rs.	1.2	0.7	
NET PROFIT BEFORE EXCEPTIONAL ITEM	188	84	123%
Exceptional item, net of taxes	(50)	-	
NET PROFIT FOR THE PERIOD	138	84	64%
# Licensing Income	13	10	
* Gross Research & Development expenses	165	136	

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	H1' FY 22	H1' FY 21	Variance %
INCOME			
Generics	1,016	1,225	-17%
Biosimilars	1,501	1,368	10%
Novel Biologics	23	-	-
Research services	1,205	941	28%
Inter-segment	(144)	(91)	59%
Revenue from operations #	3,601	3,444	5%
Other income	152	34	350%
TOTAL REVENUE	3,753	3,477	8%
EXPENDITURE			
Material & Power costs	1,327	1,229	8%
Staff costs	832	742	12%
Research & Development expenses*	266	255	4%
Other expenses	342	413	-17%
Manufacturing, staff & other expenses	2,766	2,639	5%
EBITDA	987	839	18%
Interest & Finance charges	42	19	123%
Depreciation & Amortisation	396	345	15%
Share of loss / (profit) in JV / Associate, net	107	9	100%
PBT BEFORE EXCEPTIONAL ITEM	442	466	-5%
Exceptional item	(70)	-	-
PBT	372	466	-20%
Taxes	116	103	12%
Taxes on exceptional item	(12)	-	0%
NET PROFIT BEFORE MINORITY INTEREST	268	363	-26%
Minority interest	53	45	20%
Minority interest on exceptional item	(8)	-	-
NET PROFIT FOR THE PERIOD	223	319	-30%
EPS Rs.	1.9	2.7	
NET PROFIT BEFORE EXCEPTIONAL ITEM	273	319	-14%
Exceptional item, net of taxes	(50)	-	
NET PROFIT FOR THE PERIOD	223	319	-30%
# Licensing Income	22	21	
* Gross Research & Development expenses	301	308	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	September 30, 2021	March 31, 2021
ASSETS		
Non-current assets		
(a) Property, plant and equipment	5,555	5,557
(b) Capital work-in-progress	2,788	2,254
(c) Right-of-use assets	151	153
(d) Goodwill	26	26
(e) Other intangible assets	640	627
(f) Intangible assets under development	594	547
(g) Investment in associates and a joint venture	77	180
(h) Financial assets		
Investments	342	564
Derivative assets	101	66
Other financial assets	107	201
(i) Income tax asset, net	287	265
(j) Deferred tax asset, net	292	308
(k) Other non-current assets	156	176
Non-current assets	11,116	10,922
Current assets		
(a) Inventories	2,273	1,867
(b) Financial assets		
Investments	1,406	1,209
Trade receivables	1,160	1,218
Cash and cash equivalents	663	953
Other bank balances	1,005	1,062
Derivative assets	101	83
Loans and advances	33	-
Other financial assets	660	793
(c) Other current assets	371	364
(c) Assets held for sale	-	52
Current assets	7,671	7,600
TOTAL - ASSETS	18,787	18,522
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	7,287	7,027
Equity attributable to owners of the Company	7,888	7,627
Non-controlling interests	939	881
Total Equity	8,827	8,508
Non-current liabilities		
(a) Financial liabilities		
Borrowings	3,028	2,962
Lease liabilities	103	114
Derivative liabilities	47	62
Other financial liabilities	1,503	1,503
(b) Provisions	116	106
(c) Deferred tax liability, net	36	32
(d) Other non-current liabilities	1,088	1,025
Non-current liabilities	5,920	5,805
Current liabilities		
(a) Financial liabilities		
Borrowings	1,594	1,397
Lease liabilities	19	8
Trade payables	1,382	1,514
Derivative liabilities	26	26
Other financial liabilities	310	382
(b) Provisions	123	109
(c) Income tax liability, net	174	152
(d) Other current liabilities	412	581
(e) Liabilities classified as held for sale	-	40
Current liabilities	4,040	4,210
TOTAL - EQUITY AND LIABILITIES	18,787	18,522